Research programme: protease inhibitors - Plexxikon
Latest Information Update: 07 Jul 2022
At a glance
- Originator Plexxikon
- Class Small molecules
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 06 Jul 2022 Discontinued - Preclinical for Hypertension in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertension in USA (PO)
- 04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company